Deals


  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Orna, a circular RNA specialist, acquires a buzzy startup

    After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

    By May 23, 2024
  • Two people in laboratory gowns inspect biotechnology equipment with lettering spelling Millipore.
    Image attribution tooltip
    Courtesy of Millipore Sigma via Business Wire
    Image attribution tooltip

    Merck KGaA to buy gene therapy tools maker for $600M

    The German drugmaker is bolstering its MilliporeSigma business with a unit of Gamma Biosciences that specializes in so-called transfection reagents.

    By Kristin Jensen • May 23, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to buy Proteologix and its dual-targeting antibody drugs for $850M

    The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development. 

    By Kristin Jensen • May 16, 2024
  • A scientific illustration of amyloid plaques and neurons, colored in blue and orange.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune

    The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”

    By May 13, 2024
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug

    The deal gives the pharma partial rights to a medicine GSK once developed for heart disease but could soon become the first therapy for facioscapulohumeral muscular dystrophy.

    By May 13, 2024
  • A composite image of two headshots, featuring Maze CEO Jason Coloma and CMO Harold Bernstein.
    Image attribution tooltip
    Permission granted by Maze Therapeutics
    Image attribution tooltip

    Maze lands new partner for Pompe drug, after Sanofi pact came apart

    An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission.

    By May 10, 2024
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Royalty Pharma pays startup $525M for stake in Sanofi MS drug

    The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

    By Kristin Jensen • May 9, 2024
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo taps another Flagship startup in search for next obesity drugs

    The deal with Metaphore Biotechnologies is the third from a Flagship alliance meant to boost the Danish drugmaker’s pipeline of weight loss medicines.

    By May 9, 2024
  • An illustration of two lungs on a scientific background colored orange.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    Gossamer sells rights to drug it hopes can rival a new Merck therapy

    One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

    By May 6, 2024
  • A sign reading Novartis is seen on the side of a building viewed through trees.
    Image attribution tooltip
    Novartis
    Image attribution tooltip

    Why selling to Novartis made sense for Mariana

    Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."

    By May 3, 2024
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis to buy Mariana Oncology in radiopharmaceutical expansion

    The $1 billion dollar acquisition will add to Novartis’ pipeline of the targeted radiation drugs, giving it a potential lung cancer treatment.

    By May 2, 2024
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Deciphera to sell for $2.4B, adding to upswing in biopharma M&A

    For Japan-based Ono Pharmaceutical, buying Deciphera offers a way to build out in cancer research as well as get a stronger foothold in the U.S. and European markets.

    By April 29, 2024
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen: Don’t expect any big acquisitions this year

    While the company is eager to diversify, CEO Chris Viehbacher said any near-term dealmaking would likely focus on collaborations and early-stage assets.

    By April 24, 2024
  • An Ipsen site in Wrexham, UK.
    Image attribution tooltip
    Courtesy of Ipsen
    Image attribution tooltip

    Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

    The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA. 

    By April 22, 2024
  • A scientific illustration of amyloid plaques and neurons, colored in blue and orange.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Eisai hunts for next Alzheimer’s drug with new research pact

    A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.

    By April 22, 2024
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Alvotech deal could heighten biosimilar pressure on Humira

    The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

    By April 19, 2024
  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Nemes Laszlo via Getty Images
    Image attribution tooltip

    Roche, Adaptimmune part ways on cell therapy research

    The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

    By April 12, 2024
  • NK Cell (Natural Killer Cell) Attacking a Cancer Cell
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Emerging biotech

    Century buys a startup, raises funding in cell therapy expansion

    The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.

    By April 11, 2024
  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex to buy kidney disease drugmaker Alpine for $4.9B

    A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.

    By Updated April 11, 2024
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to acquire Shockwave Medical for $13.1B

    The deal comes just over a week after The Wall Street Journal reported the companies were discussing a merger.

    By Ricky Zipp • Updated April 5, 2024
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry

    The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.  

    By Kristin Jensen • April 3, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Acorda files for bankruptcy, reveals asset sale plan

    Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

    By April 2, 2024
  • Claudia Ulbrich, CEO, Cardior Pharmaceuticals
    Image attribution tooltip
    Permission granted by Cardior
    Image attribution tooltip

    ‘The heart is back,’ says Cardior CEO, as Novo’s $1B deal boosts field

    Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior head Claudia Ulbrich.

    By Michael Gibney • March 28, 2024
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie to buy immune drug developer Landos

    Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

    By March 25, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo to acquire heart failure drug in $1B deal for Cardior

    Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.

    By March 25, 2024